

REFERENCES

1. **Adner, M., Jansen, I. And Edvinsson, L. (1994):**
Endothelin A receptors mediate contraction in human cerebral, mesangial and temporal arteries.
J. Auton. Nerv. Syst.; 49: S117.
2. **Alabadie, J.A., Salmon, J.B. and Torregosa, G. (1994):**
Changes in the cerebrovascular effects of endothelin-1 after experimental subarchanoid hemorrhage.
Surgery; 33(4): 707.
3. **Alferedo, C., Andrew, S., and Margulies, K. (1993):**
Physiological significance of endothelin: Its role in congestive heart failure.
Circulation, 87(5): V45.
4. **Alford, F.P. and Best, J.D. (1986):**
The etiology of type II diabetes. In: Recent advances in Diabetes Mellitus, 1st edition, Longman group, U.K., Vol. II: 1-22.
5. **Alkjaer, C. and Heagerty, A.M. (1987):**
Evidence of increased media thickness and increased neuronal uptake of amines in hypertensives
Circulation, Res., 61:181.
6. **Allred, E., Bleeker, E.R. and Chairman, B.R. (1989):**
Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease.
N. Engl. J. Med.; 321: 1426-32.
7. **Anggard, E., Galton, S. and Rae, G. (1989):**
The fate of radioiodinated endothelin-1 and endothelin-3 in the rat
J. Cardiovasc. Pharmacol.; 13(Suppl. 5): 645-55.
8. **Arai, H., Koshi, T., Ehara, Y., Edano, T., Ohkuchi H. and Hirata, M. (1992):**
Characterization of immunoreactive endothelin in human urine.
Biophys. Res. Commun.; 182: 1506-19.
9. **Asakura, H., Jokaji, H. and Saito, M. (1992):**
Role of endothelin-1 in disseminated intravascular coagulopathy.
Am. J. Hematol.; 41(2): 71.
10. **Austin, M.A. (1991):**
Plasma triglyceride and coronary heart disease.

Atherosclerosis; 11:2-14.

11. **Baba, T; Kodama, T., Yasuda, L.K. and Ishizaki, T (1993):**
Comparison of platelet aggregability in Japanese type 2 diabetic patients with and without microalbuminuria.
Diabet. Med. 10 (7) : 643-6
12. **Bakris, G., Fairbanks, R., and Traish, A. (1991):**
Arginine vasopressin stimulates human mesangial cell production of endothelin.
J. Clin. Invest.; 87:1158.
13. **Balzy, I., Dechaux, M. and Charbit, M. (1994):**
Endothelin-1 in children with chronic renal failure.
Ped. Nephrol.; 8(1): 40.
14. **Barnes, P.J. (1994):**
Endothelins and pulmonary diseases.
J. Appl. Physiol.; 77(3): 1051.
15. **Barrette-Connor, E.L. (1985):**
Obesity, atherosclerosis and coronary artery disease.
Ann. Inter. Med., 103: 1010-9.
16. **Barrette-Connor, E. and Tee, K. (1989):**
Cigarette smoking and increased central adiposity.
Ann. Intern. Med.; 111: 783-7.
17. **Battistini, B., D'Orleans, P.J. and Sirois, P. (1992):**
Les endothelins et le poumon.
Med. Sci; 8: 679-87.
18. **Battistini, B., D'Orleans, P.J. and Sirois, P. (1993):**
Endothelins: Circulating plasma levels and presence in other biologic fluids.
Laboratory Investigating; 68(6): 600-27.
19. **Baum, M. (1987):**
Insulin stimulates volume absorption in the rabbit proximal convoluted tubule.
J. Clin. Invest., 79 :1104-9.
20. **Bedford, B.A., Sowers, R.J. and Zemel, P. (1990):**
Increased sodium-lithium counter transport in black non-insulin dependent diabetic hypertensives.
Am. J. Hypertens.; 3: 563-5.

21. **Bennett, P.H., Haffner, S. and Kasiske, B.L. (1995):**
Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on diabetes mellitus of the National Kidney foundation
Am. J. Kidney Dis.; 25(1): 107-12.
22. **Benowitz, N.L. (1988):**
Pharmacologic aspects of cigarette smoking and nicotine addiction.
N. Eng. J. Med.; 319: 1318-30.
23. **Bernhardt, J., Tschudi, M.R. and Dohi, Y. (1991):**
Release of nitric oxide from human vascular smooth muscle cell.
Biochem. Biophys. Res. Commun.; 180: 907-12.
24. **Bjorntorp, P. (1990):**
Classification of obese patients and complications related to the distribution of fat.
Nutrition; 6: 131.
25. **Blankenhorn, D.H., Nessim, S.A. and Johnson, R.I. (1987):**
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graft.
JAMA; 257:323-40.
26. **Bloch K.D., Friedrich, S.P., Lee, M.E., Eddy, R.L., Shows, T.B., Quertermous, T. (1989):**
Structure organization and chromosomal assignment of the gene encoding endothelin.
J. Biol. Chem.; 264: 10851-8.
27. **Bobik, A., Williams, T. and Chambell, J.H. (1993):**
Vascular derived growth factors: Cell biology, pathophysiology and pharmacology.
Pharmacol. Rev.; 45: 1-42.
28. **Boden, G., Master, R.W., Gordon, S.A., Shuman, C.R. and Owen, O.E. (1980):**
Monitoring metabolic control in diabetic outpatients with glycosylated hemoglobin.
Ann. Intern. Med.; 92:357-60.
29. **Bogardus, C., Lillioja, S. and Ravussin, F. (1986):**
Familial dependence of the resting metabolic rate.
N. Eng. J. Med.; 315 96-100.

30. **Boulanger, C., Tanner, F.C. and Bea, M.L. (1992):**
Oxidant injury and release of endothelin from human and porcine endothelium.
Circ. Res., 70:119.
31. **Braddon, F.E.M., Rodgers, B., Wadsworth, M.E.J. and Davies, J.M.C. (1986):**
Onset of obesity in a 36-year birth cohort study.
Br. Med. J.; 293: 299 – 303.
32. **Brands, M.W., Hildebrandt, D.A., Mizelle, H.L. and Hall, J.R. (1992):**
Hypertension during chronic hyperinsulinemia in rat is not salt sensitive.
Hypertension; 19 (Suppl. I): 183-9.
33. **Bray, G.A. (1989):**
Autonomic and endocrine factors in the regulation of energy balance.
Federation Proceeding, 45: 1404.
34. **Bray, G.A. (1989):**
Classification and evaluation of the obesities.
Medical Clinics of North America, 73:161-84.
35. **Brenner, B.M., Garcia, D. and Anderson, S. (1988):**
Glomeruli and blood pressure.
Am. J. Hypertens.; 1: 335-47.
36. **Brenner, B.M., Troy, J. and Berlmann, L. (1989):**
Endothelium dependent vascular responses.
J. Clin. Invest., 84:1373.
37. **Brickman, A.S., Nyby, M.D., Hungen, K., Eggena, P. and Tuch, M.L. (1990):**
Calciotropic hormones, platelet calcium and blood pressure in essential hypertension.
Hypertension; 16:515-22.
38. **Brown, A., Birhaumer, L. and Wang, B. (1988):**
Direct G protein gating of ion channels.
Am. J. Physiol.; 254: H401.
39. **Budrkf, K., Murray, J. and Breyer, M. (1989):**
Mesangial cell glomerular and renal vascular response to endothelin in the rat kidney.
J. Clin. Invest.; 83: 336.

40. **Buhler, F.R., Resink, T.J., Tkackuk, V.A., Zschauer, A., Dimtrov, D., Raine, A.E.G., Bolli, P., Muller, F.B. and Erne, P. (1986):**
Abnormal cellular calcium regulation in essential hypertension.
J. Cardiovasc. Pharmacol.; 8: (Suppl. 8): S145-9.
41. **Bumagarter, S., Wagner, O. and Nowotny, P. (1994):**
Stimulation of endothelin-1 production by thrombin, but lack of interference by high ambient glucose in vitro.
Eur. J. Endocrinol.; 130(3): 271.
42. **Bunn, H.P., Briechl, R.W., and Kamin, S. (1970):**
The interaction of 2,3-diphosphoglycerate with various human hemoglobin.
J. Clin. Invest., 49: 1088-95.
43. **Bunn, H.P., Haney, D.N., Gabbay, K.H. and Gallop, P.M. (1975):**
Further identification of the nature and linkage of the carbohydrate in hemoglobin A_{1c}.
Biochem. Biophys. Res. Commun., 67:103-109.
44. **Bunn, H.F., Haney, D.N. and Kamin, S. (1976):**
The biosynthesis of human hemoglobin A. Slow glycosylation of hemoglobin in vivo.
J. Clin. Invest., 57:1652-9.
45. **Byny, R.L., Loverde, M., Lloyd, S., Mitchell, W. and Draznin, B. (1992):**
Cytosolic calcium and insulin resistance in elderly patients with essential hypertension.
Am. J. Hypertens.; 5: 459-64.
46. **Cao, L. and Banks, R.O. (1990):**
Cardiovascular and renal action of endothelin: Effects of calcium channel blockers.
Am. J. Physiol.; 258: F154.
47. **Caraway, W.T. and Watts, N.R.B. (1987):**
Diagnostic strategies of D.M. In: Tietz, N.W., *Fundamentals of Clinical Chemistry*, 3rd ed., W.B. Saunders Co. Philadelphia; 422-46.
48. **Cardell, L.O., Uddman, R. and Edvinsson, L. (1994):**
Endothelin: A role in cerebrovascular disease?
Cephalagia; 14(4): 159.
49. **Cardillo, C., Kilcoyne, C.M., Wacławiw, M., Cannon, R.O. and Panza, J.A. (1999):**
Role of endothelin in the increased vascular tone in patients with essential hypertension.

- Hypertension; 33(2): 753-8.
50. **Carretero, O.A., Scicli, A.G. and Bolli, G. (1988):**
 Kinins: Paracrine hormones.
 Kidney Int.; 34 (Suppl. 26): S52-9.
 51. **Carstensen, J.M., Pershagen, G. and Eklund, G. (1987):**
 Mortality in relation to cigarette and pipe smoking: 16 years' observation of 25,000 Swedish men.
 J. Epidemiol. Commun. Health; 41: 16-72.
 52. **Castelli, W.P., Garrison, R.J. and Wilson, P.W. (1986):**
 Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.
 JAMA; 256: 2835-8.
 53. **Chen, G., Yamamoto, Y., Miwa, K., Suzuki, H. (1992):**
 Hypertension: Smooth Vascular muscle spasm induced by endothelial humoral substances.
 Am. J. Physiol.; 255: S33-7.
 54. **Chew, B., Wever, D. and Gross, P.M. (1995):**
 Dose-related potent stimulation by a neuropeptide endothelin-1 after intraventricular administration in conscious rats.
 Pharmacol. Biochem. Behav.; 51(1): 37.
 55. **Chijawa, Y., Okabe, H. and Akiho, H. (1992):**
 Functional endothelin-1 receptors on gastric smooth muscle cells.
 Digestion; 56(2): 171.
 56. **Christensen, C.K. and Mongensen, C.E. (1985):**
 The course of incipient diabetic nephropathy. Studies of albumin excretion and blood pressure.
 Diab. Med.; 2: 97.
 57. **Colin, I., Selvais, P. and Rebai, T. (1994):**
 Expression of endothelin-1 gene in rat thyroid gland and changes in its peptide and messenger RNA levels.
 N. Eng. J. Med.; 310: 617-20
 58. **Collins, R. (1990):**
 Blood pressure, stroke, and coronary heart disease
 Lancet; 335: 827-9.

59. **Compagnucci, P., Cariechini, M.G., Bolli, G., De-Feo, P., Santeusano, F. and Brunetti, P. (1981):**
The importance of determining irreversibly glycosylated hemoglobin in diabetes.
Diabetes; 30: 607-17.
60. **Compese, V.M., Thomas, C. and Fitz, A. (1994):**
Salt sensitivity in hypertension: Renal and cardiovascular implications.
Hypertension; 23: 531-50.
61. **Corea, L., Bentivoglio, M., Savino, K. and Zollino, L. (1991):**
Recent findings in the pathophysiology of hypertension.
Cardiologia.; 36 (Suppl. 1): 51-8.
62. **Corvol, P., Clauser, E. and Waeber, B. (1989):**
Circulating and tissue rennin angiotensin systems.
J. Cardiovasc. Pharmacol.; 14(Suppl. 4): V-VI.
63. **Cottone, S., Vadala, A., Vella, M.C., Mule, G., Contorno, A. (1998):**
Comparison of tumor necrosis factor and endothelin-1 between essential and renal hypertensive patients.
J. Hum. Hypertens.; 12(6): 351-4.
64. **Cruickshank, M., Neil, D.G. and Dorrance, D.E. (1989):**
Acute effects of smoking on blood pressure.
J. Hypertens.; 3: 443.
65. **Cybulski, A.V., Stewart, D.V. and Cybulsky, M. (1993):**
Glomerular epithelial cells produce endothelin-1.
J. Am. Soc. Nephrol.; 3: 1398.
66. **Davi, G. and Aversa, M. (1988):**
Platelet function in patients with diabetes.
Diabetes Res.; 10: 7.
67. **David-Bar, S.Z. and Naparstek, Y. (1981):**
Glycosylated hemoglobin and late complications of diabetes mellitus.
N. Eng. J. Med.; 304(6): 1607-8.
68. **Davis, J.W., Shelton, L. and Eigeenberg, D.A. (1985):**
Effects of tobacco and non-tobacco smoking on endothelium and platelets.
Clin. Pharmacol. Ther.; 37: 529-33.
69. **DCCT Research Group (1993):**
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

N. Eng. J. Med.; 14: 977-86.

70. Deanfield, J.E., Shea, M.J. and Wilson, B.A. (1986):

Direct effects of smoking on the heart: Silent ischemic disturbances of coronary flow.

Am. J. Cardiol.; 57; 1005-9.

71. Deckert, T., Andersen, A.R., Christiansen, L.S. and Andersen, J.K (1981):

Diabetic nephropathy.

Acta Endocrinol.; 97(Suppl. 1) 14.

72. Defronzo, R.A. (1990):

What is the clinical impact of insulin resistance as a risk factor? In: Treatment of hypertension: Can we balance the risks? Highlights of a satellite symposium of the 13th Scientific Meeting of the International Society of Hypertension; Montreal, Jun. 24; Pp: 10-15.

73. De-Mattia, G., Cassone-Faldetta, M., Bellini, C., Bravi, M.C., Laurenti, O., Baldoncini, R., Santucci, A. and Ferri, C. (1998):

Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy.

Am. J. Hypertens., 11(18 pt 1): 983-8.

74. De-Nucci, G, Thomas, R. and D'Orleans-Juste, P. (1988):

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor

Proc. Natl. Acad. Sci.; 85: 9797.

75. De-Oliveira, A., Viawanathan, M. and Capsoni, S. (1995):

Characterization of endothelin-1 receptors cerebral and peripheral arteries of the rat.

Peptides; 16 (1): 139.

76. DHHS (US Department of Education and Welfare) (1983):

The Health Consequences of Smoking: 25 years of Progress.

DHHS Publication, No. (PHS) 84:50204.

77. DHHS (US Department of Health and Human Services) (1990):

Reducing the Health Consequences of Smoking: 25 years of Progress.

DHHS Publication, No. (CDC) 90: 8411.

78. Ditzel, J. (1975):

Eye and systemic disease, 1st ed. St. Louis, Mosby, Pp: 179.

79. **Ditzel, J. and Jens-Jorgen, K. (1978):**
Hemoglobin A_{1c} concentration after initial insulin treatment for newly discovered diabetes.
Br. Med. J.; 741.
80. **Doumas, B.T. (1971):**
Colorimetric estimation of albumin.
Clin. Chim. Acta; 31: 87.
81. **Drazin, B. (1993):**
Cytosolic calcium and insulin resistance.
Am. J. Kidney Dis.; 21(6 Suppl. 3): 32-8.
82. **Druml, W., Steltzer, H. and Walhausl, W. (1993):**
Endothelin-1 in adults respiratory distress syndrome.
Am. Rev. Respir. Dis.; 148(3): 1169.
83. **Dupont, A.G. (1993):**
Renal hemodynamics in hypertension: effects of antihypertensive drugs.
J. Hum. Hypertens.; 7(Suppl. 1): S42-5.
84. **Eddahibi, S., Raffesttin, B., Brauet, D., Chabrier, P.E. and Anot, S. (1991):**
Pulmonary vascular reactivity to endothelin-1 in normal and chronically pulmonary hypertension rats
J. Card. Pharmacol; 17(7): S358.
85. **Ehrenich, H., Rieckmann, P. and Sinowartz, M. (1993):**
Potent stimulation of monocytic endothelin-1 production by HIV glycoprotein 120.
J. Immunol.; 150(10): 4601.
86. **Emori, T., Hitara, Y. and Kanno, K. (1991):**
Endothelin-3 stimulates production of endothelium-derived nitric oxide via phosphoinositol breakdown.
Biochem. Biophys. Res. Commun; 174: 228.
87. **Epstein, M. and Sowers, J.R. (1992):**
Diabetes and hypertension
Hypertension; 19: 403-18.
88. **Esler, M., Lambert, G., and Jennings, G. (1990):**
Increased regional sympathetic nervous activity in human hypertension: Causes and consequences.
J. Hypertens; 8(Suppl. 7): S53-7.

89. **Ewing, D.J., Campbell, I.W. and Clarke, B.F. (1980):**
Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications.
Ann. Intern. Med.; 92: 308-11.
90. **Fayed, I., Zaki, A.M., Hafiez, A.A., Tawadrous, G.A., Abou Zekry, M., Karas, M.S., Abdel Monem, A.M. and El-Miligy, D. (1986):**
Glycosylated hemoglobin in chronic liver disease and acute hemolytic anemia
The Gaz. Of Egypt Soc. Ped. Assoc; 16: 174-178.
91. **Feletou, M., and Vanhoutte, P.M. (1988):**
Endothelium dependent hyperpolarization of canine coronary smooth muscle.
Br. J. Pharmacol; 93: 515-24.
92. **Ferrannini, E. (1992):**
The insulin resistance syndrome.
Curr. Opin. Nephrol Hypertens.; 1: 291-8.
93. **Ferrannini, E. (1993):**
Insulin resistance and hypertension: Connection with sodium metabolism.
Am. J. Kidney Dis.; 21(Suppl. 2): 37-42.
94. **Ferrari, P., Weidmann, P., Shaw, S., Giachino, D., Risen, W. (1991):**
Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensives parent.
Am. J. Med.; 91: 589-93.
95. **Ferrer, I.A. (1985):**
Diabetes mellitus in Huntington's disease.
Clin. Gent.; 27: 62.
96. **Ferri, C., Piccoli, A., Properzi, G., Bellini, C., Pittoni, V., Valesini, G. and Santucci, A. (1994):**
Insulin induces endothelin-1 release from human cultured endothelial cells.
J. Hypertens; 12 (Suppl.3): S127.
97. **Ferri, C., Bellini, C., Desideri, G., Baldoncini, R., Properzi, G., Santucci, A. and De-Mattia, G. (1997a):**
Circulating endothelin-1 levels in obese patients with the metabolic syndrome.
Exp. Clin. Endocrinol. Diabetes; 105 (Suppl. 2): 38-40.

98. **Ferri, C., Bellini, C., Desideri, G., Baldoncini, R., De-Siati, L. and Santucci, A. (1997b):**
Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities.
Diabetologia; 40 (1): 100-2.
99. **Fernandez, D., De-Jaun, J.A. and Zimman, H. (1994):**
Identification of endothelin 5receptor subtype ET-B receptor in human cerebral cortex
100. **Firth, J.D. and Ratcliffe (1992):**
Organ distribution of the three-rat endothelin messenger RNA and the effects of the ischemia on renal gene expression
J. Clin. Invest.; 90: 1023.
101. **Fisher, R.A. (1964):**
Statistical methods for research workers, 10th ed., Oliver and Boyd, Edinburgh.
102. **Fogelson, B.G., Nawas, S.I., Vigneswaran, W.T., Ferguson, J.L., Law, W.R. and Sharma, A.C. (1998):**
Diabetic patients produce an increase in coronary sinus endothelin-1 after coronary artery bypass grafting.
Diabetes; 47(17): 1161-3.
103. **Folkow, B. (1987):**
Structure and function of arteries in hypertension.
Am. H. J.; 114: 938.
104. **Fortaloppi, F., Vergnani, L., Degliuberti, E.C. (1993):**
Atrial natiuretic peptide and circadian BP regulation: Clues from a chronobilological approach.
Chronobiol. Int.; 10: 176-89.
105. **Fried, L.P., Moore, R.D. and Pearson, T.A. (1986):**
Long-term effects of cigarette smoking and moderate alcohol consumption on coronary diameter. Mechanisms of coronary artery disease independent of atherosclerosis or thrombosis?
Am. J. Med.; 80: 37-44.
106. **Frohlich, E.D. (1987):**
Haemodynamic consideration in clinical hypertension.
JAMA; 2600: 512-4.

107. **Fukuda, Y., Nishibe, M. and Ohata, Y. (1992):**
Analysis of responses to endothelin in isolated porcine blood vessels by using a novel endothelin antagonist BQ-123.
Life sci.; 50: 107.
108. **Fyhrquist, F., Saijonmaa, O. and Metsarinne, K. (1990):**
Atrial natriuretic peptide and nitroglycerine reduce endothelin secretion from cultured endothelial cells.
Am. J. Hypertens.; 3: 90.
109. **Gabbay, K.H., Sosenko, J.M., Banuchi, G.A., Mininsohu, M.J. and Fluckiger, R. (1979):**
Glycosylated hemoglobins: Increased glycosylation of hemoglobin A in diabetic patients.
Diabetes; 28: 337-40.
110. **Gale, H. (1988):**
Mortality associated with hypertension.
Circulation; 77(3): 504-14.
111. **Galest, J., Joureaux, C. and Sanchez, A. (1991):**
Endothelin action in rat liver: Receptor free CO₂, oscillation and activation of glycogenolysis.
J. Clin. Invest.; 87: 133.
112. **Gambara, G., Verlato, F., Budakovic, A., Casara, D., Saladini, G., Del-Prete, D., Bertaglia, G., Masiero, M., Checchetto, S. and Baggio, B. (1998):**
Renal impairment in chronic cigarette smokers.
J. Am. Soc. Nephrol.; 9(4): 562-7.
113. **Gans, R.O.B., Toorn, L., Bilo, H.J.G., Nauta, J.J.P. and Heine, R.J. (1991):**
Renal and cardiovascular effects of exogenous insulin in healthy volunteers.
Clin. Sci.; 80: 219-25.
114. **Gardener, D.G., Newman, S. and Nakamura, K. (1991):**
Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes.
Am. J. Physiol/; 216: E177.
115. **Garrow, J. (1990):**
Obesity and related diseases.
Med. Intern. J.; 82: 3382-5.

116. **Gellai, V., Sarschilli, P. and Firenze, C. (1994):**
Endothelin-1 in migraine and tension type headache.
Acta Neurol. Scand.; 89(1): 47.
117. **George, F. (1989):**
Nutrient balance and obesity: An approach to control food intake in humans.
Med. Clin. North Am.; 73(1): 29.
118. **George, F. and Cahill, J., (1985):**
General concepts of diabetes, Joslin, D.M., (ed.), 12th ed., Leo & Febger, Philadelphia; Pp: 11.
119. **Gerbase-Delima, M., Ladalardo, M.A. and Delima, J.J. (1992):**
Essential hypertension and histocompatibility antigens: An association study.
Hypertension; 19: 400-2.
120. **Ghalloungui, P. and Ghareeb, A. (1978):**
Endocrine diseases and some common metabolic disorders. Dar El-Amal El-Arabi, 4th ed.; Pp: 124.
121. **Giald, A., Yanagisawa, M. and Langleben, D. (1993):**
Expression of endothelin-1 in the lung of patients with pulmonary hypertension.
N. Eng. J. Med.; 328(4): 1732.
122. **Giald, A., Saleh, D., Yanagisawa, M. and Forbes, R. (1995):**
Endothelin-1 immunoreactivity and mRNA in the transplanted human heart.
Transplantation; 59(9): 1308.
123. **Gilbert, R.E., Cooper, M.E. and McNatly, P.G. (1994):**
Microalbuminuria: Prognostic and therapeutic implications in diabetes mellitus.
Diabet. Med.; 11(7): 636-45.
124. **Goetez, K., Wang, B. and Madwed, J. (1989):**
Cardiovascular, renal and endocrine response to intravenous endothelin in conscious dogs.
Am. J. Physiol//; 255: R1064.
125. **Goldstein, D.E., Parker, K.M., England, J.D., Wiedmeyer, J.R., Rowlings, S.S., Randle, R.M., Smonds, J.F. and Breyfogle, R.P. (1982):**
Clinical application of glycosylated hemoglobin measurements.
Diabetes; 31 (Suppl. 3): 70-8.

126. **Gonen, H. and Rubenstein, S. (1978):**
Biosynthesis of human hemoglobin A1c. slow glycosylation of hemoglobin in vivo
J. Clin. Invest.; 60: 1331.
127. **Gravey, H.T., Birnbaum, M.J. Horton, E.S. (1993):**
Cellular insulin action and insulin resistance. In: Bailliere's Clin. Endocrinol. Metab.; 7: 785-873.
128. **Gray, D.S. (1989):**
Diagnosis and prevalence of obesity.
Med. Clin. North Am.; 73: 1-13.
129. **Grobbbee, D.E. (1994):**
Electrolytes and hypertension: Results from recent studies.
Am. J. Med. Sci.; 307(Suppl. 1): S17-20.
130. **Groop, L., Ekstrand, A. and Forsblom, C. (1993):**
Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin dependent) diabetes mellitus.
Diabetologia; 36(7): 642-7.
131. **Gross, P.M., Benign, R.J. and Shaver, S. (1993):**
Metabolic and neuroanatomical correlates of barrel-rolling and oculoclonic convulsions induced by intraventricular endothelin-1: A novel peptidergic signaling mechanism in visuovestibular and oculomotor regulation?
Exp. Brain Res.; 93(3): 397.
132. **Gunning, M., Ingelfinger, J., King, A. and Brenner B. (1996):**
Endothelin-1 in pulmonary hypertension associated with high altitude exposure.
Circulation; 91(1): 359.
133. **Gupta, A.K., Clark, R.V. and Kirchner, K.A. (1992):**
Effects of insulin on renal sodium excretion.
Hypertension, 19(Suppl. 1): 178-82.
134. **Guerre, S., Wenk, M. and Bartson, P. (1994):**
Endothelin-1 in pulmonary hypertension associated with high altitude exposure.
Circulation; 91(1): 359.
135. **Guthrie, H.A. (1986):**
Introductory Nutrition, 6th ed., Mosby Publishing; Pp: 158-69.

- 136. Guyton, A.C. (1991):**
Endocrinology, metabolism and temperature regulation, obesity and starvation. In: Guyton, A.C., Textbook of Medical Physiology, 8th ed., W.B. Saunders Co., Philadelphia; Pp: 759.
- 137. Haffner, S.M., Frong, D. and Hazuda, H.P. (1988):**
Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics.
Metabolism; 37: 338-45.
- 138. Hagger, A., Sjostrom, L., Arvidsson, B., Bjorntrop, P. and Smith U. (1977):**
Body fat and adipose tissue cellularity in infants: A longitudinal study.
Metabolism; 26: 607-10.
- 139. Halawa, B. and Mazurek, W. (1997):**
Circadian urinary excretion of catecholamine, plasma atrial natriuretic peptide, endothelin and neuropeptide Y in obese patients with hypertension.
Pol. Arch. Med. Wewn.; 98(11): 407-13.
- 140. Hall, J.E., (1993):**
Hyperinsulinemia: A link between obesity and hypertension.
Kidney Int.; 43: 1402-17.
- 141. Hall, J.E., (1994):**
Renal and cardiovascular mechanisms of hypertension in obesity.
Hypertension; 23: 381-94.
- 142. Hall, J.E., Brands, M.W., Zappe, D.H. and Galacia, M.A. (1995):**
Insulin resistance, hyperinsulinemia and hypertension: Causes, consequences or merely correlations?
Proc. Soc. Exp. Biol. Med.; 208: 317-29.
- 143. Hamasaki, H., Sato, J., Masuda, H., Tamaoki, S., isotani, E., Obayashi, S., Udagawa, T. and Azuma, H. (1997):**
Effect of nicotine on the intimal hyperplasia after endothelial removal of rabbit carotid artery.
Gen. Pharmacol.; 28(5): 653-9.
- 144. Hamsten, A., Walldius, G., Szamosi, F., Blomback, M., Faire, U., Dahlen, G., Landou, C. and Wiman, B. (1987):**
Plasminogen activator inhibitor in plasma, a risk factor for recurrent myocardial infarction.
Lancet; 1:3-8.

- 145. Han, H., Neubeur, S., Bracker, B. and Ertl, G. (1995):**
Endothelin-1 contribute to ischemia/reperfusion injury in isolated rat heart
attenuation of ischemic injury by the endothelin-1 antagonis BQ-123 and
BQ610.
J. Mol. Cell Cardiol.; 27(2): 671.
- 146. Harter, E. and Woloszczuk, W. (1989):**
Radioimmunoassay of endothelin.
Lancet; 1: 909.
- 147. Harts, A.J., Barboriak, P.N. and Anderson, A.J. (1981):**
Smoking, coronary artery occlusion and non-fatal myocardial infarction.
JAMA; 246: 851-3.
- 148. Heagerty, A.M. (1994):**
Hypertension: Hypertrophy, remodeling and dysfunctional endothelium.
J. Vasc. Med. Biol.; 5(3): 107-10.
- 149. Helset, E., Sildness, T. and Konopski, Z. (1994):**
Endothelin-1 stimulates monocytes in vivo to release chemotactic activity
identified as interleukin 8 and monocyte chemotactic protein 1.
Mediators Inflamm.; 3(2): 155.
- 150. Henry, J. (1984):**
Clinical diagnosis and management by laboratory methods, Todd, Sanford
Davidson, (eds.), W.B. Saunders Co., Philadelphia, Vol. 1: 175.
- 151. Higgins, P.J., Garlich, R.L. and Bunn, H.F. (1982):**
Glycosylated hemoglobin in human and animal red cells: Role of glucose
permeability.
Diabetes; 31:743.
- 152. Hirata, Y., Yoshimi, H. and Watanabe, T. (1989):**
Receptor binding activity and cytosolic free calcium response by synthetic
endothelin analogous in cultured rat vascular smooth muscle cells.
Biochem. Biophys. Res. Commum.; 160: 228.
- 153. Hirsch, J. and Batchelor, B. (1976):**
Adipose tissue cellularity in human obesity
Clin. Endocrinol. Metab.; 5: 299-311.
- 154. Hollister, A.S., Inagami, T., Tomy, R. (1992):**
Atrial natiuretic factor and hypertension. A review and meta-analysis.
Am. J. Hypertens.; 5: 859-61.

155. Hopfner, R.L., Misurski, D., Wilson, T.W., McNeill, J.R.
Gopalakrishnan, V. (1998a):
Insulin and vanadate restore decreased plasma endothelin concentrations
and exaggerated vascular responses to normal in the streptozocin diabetic
rat.
Diabetologia; 41(10): 1233-40.
156. Hopfner, R.L., Hasnadka, R.V., Wilson, T.W., McNeill, J.R. and
Gopalakrishnan, V. (1998b):
Insulin increases endothelin-1 evoked intracellular free calcium responses
by increased ET (A) receptor expression in rat aortic smooth muscle cells.
Diabetes; 47(6): 937-44.
157. Horton, S., Kahn, B.B. and Krittler, J. (1990):
Regulation of glucose transport.
J. Clin. Invest.; 85: 867-71.
158. Hudson, H. (1968):
Urease Berthelot method for determination of serum creatinine.
Clin. Chem.; 14: 222-38.
159. Hughes, A.D. and Schachter, M. (1994):
Hypertension and blood vessels.
Br. Med. Bull.; 50: 356-70.
160. Hurbital, M., Cunningham, M.E. and D'Auto, M. (1995):
Endothelin-1 and prostaglandin E2 levels increase in patients with burns.
J. Am. Coll. Surg.; 180(3): 318.
161. Hwang, Y.S., Hsieh, T.J., Lee, Y.J. and Tsai, J.H. (1998):
Circadian rhythm of urinary endothelin-1 excretion in mild hypertensive
patients.
Am. J. Hypertens.; 11(11pt 1): 1344-51.
162. Iimura, O., Shimamoto, K. and Abman, S. (1993):
Salt and hypertension: Water-sodium handling in ETH.
Ann. NY Acad Sci.; 676: 105-21.
163. Ikagawa, R., Matsumura, Y. and Tsukahara, Y. (1990):
Phosphoramidone, a new metalloproteinase inhibitor, suppresses the
secretion of endothelin-1 from cultured endothelial cells by inhibiting a big
endothelin-1 converting enzyme.
Biochem. Biophys. Res. Commun.; 171: 669.

- 164. Itoh, S., Saskai, T. Asia, A. and Kuchino, Y. (1994):**
Prevention of delayed vasopressin by an endothelin (A) receptor antagonist, BQ-123: Changes of ET (A) receptors mRNA expression in a canine subarachnoid hemorrhage model.
J. Neurosurg.; 81(5): 759.
- 165. Ivy, D., Kinsella, J. and Abman, S. (1994):**
Physiological characterization of endothelin A and B receptor activity in the bovine fetal pulmonary circulation.
J. Clin. Invest.; 93(3): 2141.
- 166. Izzo, J.L. (1989):**
Sympathoadrenal activity, catecholamines and the pathogenesis of vasculopathic hypertensive target organ damage.
Am. J. Hypertens.; 2(Suppl. 12): S305-12.
- 167. Izzo, J.L., Santarosa, R.P., Larrabee, P.S. (1987):**
Increased plasma norepinephrine and sympathetic nervous system activity in essential hypertensive and uremic humans.
J. Cardiovasc. Pharmacol.; 10: S225-9.
- 168. James, C.G. and Baker, P.T. (1990):**
Hereditary role in D.M. and hypertension.
Am. J. Med.; 30: 750-5.
- 169. Januszewicz, A., Tapinski, M., Symonides, B., Dabrowska, E. and Kuch-Wocial, A. (1994):**
Elevated endothelin-1 plasma concentration in patients with essential hypertension.
J. Cardiovasc. Risk; 1: 81-5.
- 170. Jarrett, R.J. and Keen, H. (1979):**
The WHO multinational study of vascular disease in diabetes.
Diabetes Care; 2: 196-201.
- 171. Jendrassik, L. (1938):**
Colorimetric determination of bilirubin in serum.
Biochem.; 7297: 81.
- 172. Jensen, T., Bjerre-Knudsen, J., Feldt-Rasmussen, B. and Deckert, T. (1989):**
Features of endothelial dysfunction in early diabetic nephropathy.
Lancet; 4: 461-3.
- 173. Jeremial, S. (1993):**
Blood pressure and cardiovascular risk.

Arch. Intern. Med.; 153: 598-615.

174. Jeunemaitre, X., Soubrier, F. and kotelevtsev, Y. (1992):

Molecular basis of human hypertension: Role of angiotensinogen.
Cell; 71: 169-80.

175. Joffer, F.E., Kneuss, T.C., Poptic, E. and Aboudd, H.E. (1990):

Endothelin stimulates PDGF secretion in cultured human mesangial cells.
Kidney Int.; 38: 1193.

176. Jones, C.R., Hiley, C., Pelton, J. and Miller, R. (1989):

Autoradiographic localization of endothelin binding sites in kidney. Eur. J.
5Pharmacol.; 163: 379.

177. Jovanovic, L. and Peterson, C.M. (1981):

The clinical utility of glycosylated hemoglobin.
Am. J. Med.; 70(12): 331.

178. Julius, S., Gudbrandsson, T., Jamerson, K. and Andersson, O. (1992):

The interconnection between sympathetics, microcirculation and insulin
resistance in hypertension.
Blood Press; 1: 9-19.

179. Kahn, B.B. (1992):

Facilitative glucose transporters: Regulatory mechanisms and
dysregulation in diabetes.
J. Clin. Invest.; 89: 1367-74.

180. Kannel, W.B. and D'Agonstino, R.B. (1989):

Cigarette smoking and risk of cardiovascular disease
Am. Heart J.; 113: 1006.

181. Kannel, W.B. and Ross, S.A. (1990):

States of insulin resistance.
Am. Heart J.; 121: 1267.

182. Kanse, S.M., Takahashi, K. and Lam, H.C. (1990):

Cytokine stimulated endothelin release from endothelial cells.
Life Sci.; 48: 1379.

**183. Kanse, S.M., Takahashi, K., Warren, J.B., Ghatie, M. and Bloom, S.R.
(1991):**

Glucocorticoids induce endothelin release from vascular smooth muscle
cells but not endothelial cells.
Eur. J. Pharmacol.; 199: 99-101.

184. Kanyiscka, B. and Freeman, M.E. (1993):

Characterization of endothelin receptors in the anterior pituitary gland.

Am. J. Physiol. Endocrinol. Metab.; 165(4): 601.

185. Kaplan, N.M. (1989):

The deadly quartet: Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension
Arch. Intern. Med.; 149: 1514-20.

186. Kaplan, N.M. (1991):

Hormonal and local factors in hypertension
Am. J. Med. Sci.; 301: 412-20.

187. Kara-Penz, H., Pupek-Musialik, D. and Kosicka, T. (1998):

Endothelin and arterial hypertension.
Pol. Merkuriusz Lek.; 4(19): 1-4.

188. Katusic, Z.S., Vanhoutte, P.M. and Horio, T. (1989):

Superoxide anion is an endothelium derived contracting factor.
Am. J. Physiol.; 257: H33-7.

189. Kaufman, H., Oribe, E. and Oliver, J.A. (1991):

Plasma endothelin during upright tilt: Relevance for orthostatic hypotension?
Lancet; 338: 1542-5.

190. Kaye, T.R. and Crapo, L. (1990):

Dyslipidemia and hypertension.
Ann. Int. Med.; 112:434.

191. King, A.J., Brenner, M.B. and Anderson, S.A. (1989):

Endothelin: A potent renal and synthetic vasoconstrictor peptide.
Am. J. Physiol; 256: F1051.

192. Kimura, S., Kasuya, Y. and Sawamura, S.A. (1988):

Conversion of big endothelin 1 to 21 residue endothelin-1 is essential for expression of full vasoconstrictor activity: Structure activity relationship of big endothelin-1.
J. Cardiovasc. Pharmacol.; 13(5): 50.

193. Kissebah, A.H., Vydlingum, N., Murray, R., Evans, D.J., Hartz, A.J.,

Kalkhoff, R.K. and Adams, P.W. (1982):

Relation of body fat distribution to metabolic complications of obesity.
Am. J. Physiol; 250: S456.

194. Kitazume, K., Shiba, T. and Nishiki, K. (1990):

Vasodilator effects of sarafotoxins and endothelin-1 in spontaneously hypertensive rat and rat isolated perfused mesentery.
Biochem. Pharmacol.; 40: 1843.

- 195. Kitujima, T., Tani, K. and Yamaguchi, T. (1995):**
 Role of endogenous endothelin in gastric mucosal injury induced by hemorrhagic shock in rats.
 Digestion; 56(2): 111.
- 196. Knon, P.G., D'Aprie, C. and Henry, P.J. (1995):**
 Receptors of endothelin-1 in asthmatic human peripheral lung.
 Br. J. Pharmacol.; 114(1): 1.
- 197. Kobri, M., Fukuushi, Y. and Tomita, M. (1994):**
 Cerebral vasodilatory effect of high dose intravenous endothelin-1: Inhibition by N (G)-monomethyle-L-arginine.
 J. Auton. Nerv. Syst.; 49: S111
- 198. Koenig, R.J, Araujo, D.C., and Cerami, A. (1976):**
 Hemoglobin A_{1c} as an indicator of the degree of glucose intolerance in diabetes.
 Diabetes; 25: 230
- 199. Kohan, D.E. (1992):**
 Production of endothelin-1 by rat mesangial cells: Regulation by tumor necrosis factors.
 J. Lab. Clin. Med.; 119(5): 477.
- 200. Kohan, D.E. and Padilla, E. (1993):**
 Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct.
 J. Clin. Invest.; 91: 1235.
- 201. Kohno, M., Yansunar, K., Murakawa, K., Yokokawa, K., Horio, T., Fukui, F. and Takeda, T. (1990):**
 Plasma immunoreactive endothelin in essential hypertension
 Am. J. Med.; 88: 614-8.
- 202. Kohno, M., Yasunar, K., Yokokawa, K., Murakawa, K., Horio, T. and Takeda, T. (1991):**
 Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin-II and thrombin of cultured human endothelial cells.
 Clin. Invest.; 87: 1999-2004.
- 203. Kolterman, O.G. (1981):**
 Receptor and post-receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus.
 J. Clin. Invest.; 68: 957.

- 204. Kon, V., Yohioko, T., Fogo, A. and Ichikawa, I. (1989):**
Glomerular actions of endothelin in vivo.
J. Invest.; 83(1): 1762.
- 205. Kraft, B., Beam, W.R. and Wenzel, S.E. (1994):**
Blood and bronchoalveolar lavage endothelin-1 in bronchial asthma.
Am. J. Respir. Crit. Care Med.; 149(4): 447.
- 206. Krishna, G.G. (1994):**
Role of potassium in the pathogenesis of hypertension.
Am. J. Med. Sci.; 307(Suppl. 1): S21-5.
- 207. Krolewski, A.S., Laffel, L.M., Krolewski, M. and Quinn, M. (1995):**
Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus.
N. Eng. J. Med.; 332(19): 1251-5.
- 208. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M. and Charlon, V. (1998):**
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension.
N. Eng. J. Med.; 328(12): 784-90.
- 209. Kukoki, M., Hirata, Y., Hayakawa, H., Tojo, A., Nagata, D., Suzuki, E., Kimura, K., Goto, A., Kikuchi, K., Nagano, T. and Omata, M. (1999):**
Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney.
Circulation; 99(9): 1242-8.
- 210. Kurtz, A., Kaissling, B., Busse, R. and Bair, W. (1991):**
Endothelial cells modulate rennin secretion from isolated mouse juxtaglomerular cells
J. Clin. Invest.; 88: 1147.
- 211. Kurtz, T.W. (1993):**
Genetics of essential hypertension.
Am. J. Med.; 94: 77-84.
- 212. Lam, H.C., Takahashi, K., Ghatel, A.M., Suda, K., Kanase, S.M. and Bloom, S.R. (1991):**
Presence of immunoreactive endothelin in human saliva and rat parotid gland.
Peptides; 12: 883-8.

213. Landin, K., Stigendal, L., Friksso, E., Krotkiewski, M., Risberg, B., Tengborn, L. and Smith, U. (1990):
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator-inhibitor-1.
Metabolism; 39: 1044-8.
214. Lapidus, L., Bengtsson, C., Larsson, B., Pennert, K., Rybo, E. and Jostrom, I. (1984):
Distribution of adipose tissue and risk of cardiovascular disease and death: A 12-year follow-up of participants in potential study of women in Gothenburg, Sweden.
Br. J. Med.; 289: 1257-61.
215. Larsson, B., Svardsudd, K., Welin, L., Wilhelmsen, L., Bjorntorp, P. and Tibblin, G. (1984):
Abdominal adipose tissue distribution and death: A 13-year follow-up of participants in the study of men born in 1913.
Br. J. Med.; 288: 1401-4.
216. Laurenti, O., Vingolo, E.M., Desideri, G.B., Ferri, C., Bellini, C., Cassone-Faldetta, M. Santucci, A. and De-Mattia, G. (1997):
Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage.
Exp. Clin. Endocrinol. Diabetes; 105 (Suppl. 2): 40-2.
217. Laustiola, K.E., Lassila, R. and Kaprio, J. (1988):
Decreased B-adrenergic receptor density and catechoalmine response in male cigarette smokers. A study of monozygotic twin pairs discordant for smoking.
Circulation; 78: 1234-40.
218. Lazaratos, S., Kashimura, H. and Nakahara, A. (1993):
Gastric ulcer induced submucosal injection of endothelin-1: A role of potent vasoconstriction and intraluminal acid.
Am. J. Physiol. Gastrointest. Liver Physiol.; 265(3): 491.
219. Lee, J.A., Brinckmann, J.R. and Longeton, E.D. (1994):
Lysine 182 of endothelin B receptor modulates agonist and antagonist affinity: Evidence for the overlap of peptide and non-peptide ligand binding sites.
Biochemistry; 33(48): 143-45.
220. Lerman, A., Heldebrandd, F.L. and Aarhus, L. (1991):
Endothelin has biological action at pathophysiological concentrations.

Circulation; 83: 1808-14.

221. Lerman, A., Click, R.L. and Narr, B.J. (1991b):

Elevation of plasma endothelin associated with systemic hypertension in human following liver transplantation
Transplantation; 15: 646.

222. Letcher, R.L., Chien, S. and Pickering, T.G. (1991):

Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects.
Am. J. Med.; 70: 1195-1205.

223. Li, K., Sirois P. and Rouleau, J.L. (1994):

Role of endothelial cells in cardiovascular function.
Life Sci.; 54: 579-92.

224. Lifton, R.P. and Jeunemaitre, X. (1993):

Finding genes that cause human hypertension.
J. Hypertens.; 11: 231-6.

225. Lithell, H., (1992):

Insulin resistance and cardiovascular drugs.
Clin. Exp. Hypertens.; 14: 151-62.

226. Loeffler, B.M. and Maire, P. (1992):

Levels of immunoreactive endothelin-1 measured in plasma are dependent upon assay conditions of the radioimmunoassay.
J. Vasc. Res.; 16: 29-60.

227. Lopez, A., Gommez-Garre, D. and Bernabeau, F. (1991):

Renal effects and mesangial cells contraction induced by endothelin are mediated by PAF.
Kidney Int.; 39: 624.

228. Lund, P. (1989):

Central hemodynamics in essential hypertension.
J. Hypertension; 7(Suppl. 6): 552.

229. Luscher, T.F. and Tanner, F.C. (1993):

Endothelial regulation of vascular tone and growth
Am J. Hypertens.; 6(Suppl. 1): S283-93.

230. Luscher, T.F., Yang, Z., Tschudi, M., VonSegesser, Stulz, P.,

Boulanger, S., Siebenmann, R., Turina, M. and Buhler, F.R. (1990):

Interaction between endothelin-1 and endothelium derived relaxing factors in human arteries and veins.
Circ. Res.; 66: 1088-94.

- 231. Luscher, T.F., Wenzel, R. and Noll, G. (1995):**
Local regulation of the coronary in the health and disease: Role of nitric oxide and endothelin.
Eur. Heart J.; 16: S51.
- 232. Ma, J.Y., Gebremedhin, D., Schwartzman, M.L., Falck, J.R., Clark, J.E. and Masters, B.S. (1993):**
Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries.
Circ. Res.; 72: 126-36.
- 233. Maddox, D.A. and Brenner, B.M. (1991):**
Glomerular ultrafiltration. In: The Kidney, Brenner, B.M. and Rector, F.C. (eds.), 4th ed., W.B. Saunders Co., Philadelphia; Pp: 205.
- 234. Mangiafico, R.A., Malatino, L.S., Santonocito, M. and Spada, R.S. (1998):**
Plasma endothelin-1 concentrations in non-insulin dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of lower limbs.
Int. Angiol.; 17(2): 97-102.
- 235. Marcus, M.L., Mueller, T.M. and Eastham, C.H. (1981):**
Effects of short and long-term left ventricular hypertrophy on coronary circulation.
Am. J. Physiol.; 24: 358-62.
- 236. Margulies, K., Frederick, L., Hildebrand, J.R., John, C. and Burnet, J.C. (1990):**
Increased endothelin in experimental heart failure.
Circulation; 82(6): 2226.
- 237. Marin, J. (1993):**
Mechanisms involved in the increased vascular resistance in hypertension.
J. Auton. Pharmacol.; 13: 127-76.
- 238. Marsden, P.A., Dorfman, D.M. and Collin, T. (1991):**
Regulated expression of endothelin-1 in glomerular capillary endothelial cell.
Am. J. Physiol.; 261: F117.
- 239. Marston, H.M., Faber, E.S. and Crawford, J. (1995):**
Behavioral assessment of endothelin-1 induced middle cerebral artery occlusion in the rat.
Neuroport.; 5(7): 1067.

- 240. Masaki, T. (1993):**
Homeostatic and compensatory actions in the circulatory and endocrine systems.
Endocr. Rev.; 14: 256-68.
- 241. Masaki, T., Yanagisawa, M., Goto, K. and Kimura, S. (1990):**
Role of endothelin in mechanisms of local blood vessels depressor control.
J. Hypertens.; 8: S101.
- 242. Matsumoto, H., Uemasu, J., Kitano, M. and Kawasaki, H. (1994):**
Clinical significance of plasma endothelin-1 in patients with chronic liver disease.
Dig. Dis. Sci.; 39(12): 2665.
- 243. Matsumura, k., Abe, L., Tsuchihashi, T., Tominaga, M., Kobayashi, k. and Fujishima, M. (1991):**
Central effects of endothelin on neurohormonal responses in coronary rabbits.
Hypertension; 17: 1192-8.
- 244. Mauer, S.M., Steffes, M.W. and Brown, D.M. (1981):**
The kidney in diabetes.
Am. J. Med.; 70: 603.
- 245. Maxwell, M.H., Waks, A.U. and Safam, G. (1987):**
Cations and hypertension: Sodium, potassium, calcium and magnesium.
Med. Clin. North Am.; 71: 859-75.
- 246. McBirde, P.E. (1992):**
The health consequences of smoking: Cardiovascular diseases.
Med. Clin. North Am.; 76(2): 333-53.
- 247. McCance, D.R., Ritche, C.M. and Kennedy, L. (1988):**
Is hemoglobin A₁ superfluous in non-insulin dependent diabetes mellitus?
Diabetes Care; 11: 512-4.
- 248. Messerli, F.H. (1982):**
Cardiovascular effects of obesity and hypertension.
Lancet; 22: 1165-8.
- 249. Messerli, F.H., Sunagaard, K., Reisin, E., Dunn, F., Dreslinski, G.R. and Frohlich, E.D. (1982):**
Left ventricular adaptation to obesity.
Am. J. Cardiol.; 49: 977.
- 250. Messerli, F.H., Numez, B.D., Ventura, H.O. and Snyder, D.W. (1987):**
Overweight and sudden death.

- Arch. Intern. Med.; 147: 1725-8.
- 251. Michida, T., Kawano, S. and Masuda, E. (1994):**
 Role of endothelin-1 in hemorrhagic shock-induced gastric mucosal injury in rats.
 Gastroenterology; 106(4): 988.
- 252. Migas, O.D. (1988):**
 The lipid effects of smoking.
 Am. Heart J.; 115: 272.
- 253. Miller, W.L., Redfeild, M. and Burnett, J.C. (1989):**
 Integrated cardiac, renal and endocrine actions of endothelin
 J. Clin. Invest.; 83: 317-20.
- 254. Minami, S., Yamano, S., Sawai, N., Nomura, K., Fukui, R., Takaoka, M., Yamamoto, Y., Nakatani, A. and Dohi, K. (1997):**
 Relationship between carotid atherosclerosis and plasma endothelin-1 concentration in senile patients with hypertension.
 Nippon. Ronen Igakkia zasshi; 34(12): 1009-16.
- 255. Mongeau, J.G. (1991):**
 Pathogenesis of essential hypertension.
 Pediatr. Nephrol.; 5(4): 404-11.
- 256. Mongensen, C.E. and Schmitz, O. (1988):**
 The diabetic kidney: From hyperfiltration and microalbuminuria to end-stage renal failure.
 Med. Clin. North Am.; 72(6): 1465.
- 257. Moore, K., Wenden, J. and Frazer, M. (1992):**
 Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.
 N. Eng. J. Med.; 327(25): 1774.
- 258. Morabito, E., Corsico, N., Serafini, N. and Martelli, E. (1994):**
 Elevated urinary excretion of endothelin in streptozotocin diabetic rats.
 Life Sc.; 54(11): 197.
- 259. Moreau, K., Brailon, A. and Roulot, D. (1989):**
 Hypoia and liver cirrhosis.
 Gastroenterology; 13: 978.
- 260. Morise, T., Takeuchi, Y. and Kawano, M. (1995):**
 Increased plasma levels of immunoreactive endothelin and VonWillebrand factor in NIDDM patients.
 Diabetes Care; 18(1): 87

- 261. Muirhead, E.E. (1993):**
Renal vasodepressor mechanism: the medullipin system.
J. Hypertens.; 11(Suppl. 5): 53-8.
- 262. Muller-Wieland, D., Streicher, R., Siemeister, G. and Krone, W. (1993):**
Molecular biology of insulin resistance
Exp. Clin. Endocrinol.; 101: 17-29.
- 263. Muller-Wieland, D., Kotzka, J., Knebel, B. and Krone, W. (1998):**
Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance.
Basic Res. Cardiol.; 93(Suppl. 2): 131-4.
- 264. Mulvany, M.J. (1993):**
Resistance vessel structure and the pathogenesis of hypertension.
J. Hypertens.; 11(Suppl. 5): 7-12.
- 265. Munger, K.A., Sagiura, M. and Takahashi, K. (1993):**
A role of atrial natriuretic peptide in endothelin induced maturessis.
J. Am. Soc. Nephrol.; 1: 1278.
- 266. Murch, S.H., Braegger, C.P. and McDonald, T. (1992):**
High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis.
Lancet; 339: 381.
- 267. Murihead, E.E. (1993):**
Renal vasodepressor mechanisms: The Medullipin system.
J. Hypertens.; 11(Suppl. 5): 53-8.
- 268. Nagao, T. and Vanhoutte, P.M. (1992):**
Hyperpolarization as a mechanism for endothelium dependent relaxations in procaine coronary arteries.
J. Physiol.; 445: 355-68.
- 269. Nakajima, K., Kubo, S. and Nishio, H. (1989):**
Structure-activity relationship of endothelin: Importance of charged groups.
Biochem. Biophys. Res. Commun.; 163: 424.
- 270. Natali, T., Santoro, D., Alambo, C., Cerri, M. and Ghione, S. (1991):**
Impaired insulin action on skeletal metabolism in essential hypertension.
Hypertension; 17: 170-8.
- 271. Nathan, D.M., Singer, D.E., Hurxthal, K. and Goodson, J.D. (1984):**
The clinical information value of the glycosylated hemoglobin assay.
N. Eng. J. Med.; 310: 341-6.

272. Neid, G.H. (1994):

Endothelin plasma levels in hypertensive patients with vascular disease.
J. Hypertens.; 12(Suppl. 1): S17-20.

273. Napoli, C., Di-Gregorio, F., Sorice, P., Di-Benedetto, A., Ciafre, S., Posca, T., Reffara, A, Paolo, E., Bruzzese, G., D'Armiento, F.P., Mansi, L. and Ligouri, A. (1997):

High prevalence of myocardial ischemia and vasoconstrictive hormonal release in hypertension during chronic renal failure.
Nephron; 76(4): 434-44.

274. Narri, S., Bruno, C.M., Ierna, D., Signorelli, S., Pennisi, G. and Andreozzi, G.M. (1997):

Endothelin-1 in arterial hypertension after cold pressor test.
Int. Andiol.; 16(4): 269-71.

275. Naylor, W.G. (1990):

Endothelin: isoforms, binding sites, and possible implication in pathology.
Trends Pharmacol. Sci.; 11:96.

276. Nombi, P., Williams, H. and Pullen, M. (1992):

Identification of endothelin receptors subtypes in rat kidney cortex using subtypes selective ligands.
Mol. Pharmacol. Exp.; 42: 336.

277. Nombi, P., Pullen, M., Jugus, M. and Gellai, S. (1993):

Rat kidney endothelin receptors in ischemia-induced acute renal failure.
J. Pharmacol. Exp.; 264(1): 345.

278. O'Brien, C.P. (1996):

Drug addiction and drug abuse. In Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. and Gilman, A.G., (eds.), W.B. Saunders Co., 1st ed., Pp:213.

279. Oishi, S., Sasaki, M. and Sato, T. (1994):

Elevated immunoreactive endothelin levels in patients with pheochromocytoma.
Am. J. Hypertension; 7(8): 717.

280. Okaba, H., Chijiwa, Y. and Yoshinaga, M. (1995):

Direct contractile effect of endothelin-1 on isolated circular smooth muscle cells of guinea pig ceceum.
Digestion; 56(1): 21

- 281. Okada, Y., Arima, T., Okazaki, S. and Nakated, R. (1982):**
Increased 125 labelled concentration binding to erythrocytes in diabetes mellitus.
Diabetologia; 22: 212.
- 282. Olefsky, J.M. (1987):**
Obesity. In: Braunwald, E., Isselbacher, K.J., Pelersdrof, F.G., Wilson, J.D., Martin, J.B. and Fauci, A.S., (eds.) Harrison's Principles of Internal Medicine, 11th ed., McGraw-Hill Book Co., New York; Pp: 1671-4.
- 283. Osterby, R. (1975):**
Early phases in the development of diabetic glomerulopathy.
Acta Med. Scand.; Suppl. 1: 475.
- 284. Osterby, R., Jackson, H. and Alfred, L. (1983):**
Basement membrane morphology in diabetes mellitus. In: Theory and Practice, Ellenberg, M. and Rifkin, H., (eds), 3rd ed., Medical Examination Publishing, New York; Pp: 323-41.
- 285. O'Sullivan, J.B., Mahan, C.M. and Charles, D. (1973):**
Gestational diabetes, maternal and fetal complications.
Am. J. Obstet. Gynecol.; 116: 895-900
- 286. Oxford, M. (1986):**
Hypertension, a major risk factor for coronary heart disease.
Am. J. Cardiol.; 50: 370-5.
- 287. Ozaki, S., Ohwaki, K. and Ihara, M. (1995):**
Et (B) mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells.
Biochem. Biophys. Res. Commun.; 209(2): 483.
- 288. Ozdemir, S., Sattoci, U. and Besbas, N. (1992):**
Plasma atrial natriuretic peptide and endothelin-1 in poststreptococcal glomerulonephritis.
Pediatr. Nephrol.; 6(6): 519.
- 289. Palmer, R., Ashton, A. and Moncada, S. (1988):**
Vascular endothelial cells synthesize nitric oxide from L-arginine.
Nature; 333: 664-6.
- 290. Parving, H.H. and Andersen, A.R. (1983):**
Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
Lancet; 28: 1175-78.

- 291. Parving, H.H., Oxenboll, B., Edsberg, B., Svendsen, P.A. Christiansen, J.S. and Andersen, A.R. (1982):**
Early detection of patients at risk of developing diabetic nephropathy: A longitudinal study of urinary albumin excretion.
Acta Endocrinol. Copeng.; 100: 550-5.
- 292. Passa, P (1992):**
Hyperinsulinemia, insulin resistance and essential hypertension.
Horm. Res.; 38: 33-8.
- 293. Peiris, A.N., Sothman, M.S. and Hoffmann, R.G. (1989):**
Adiposity and cardiovascular risk.
Ann. Int. Med.; 110: 867-72.
- 294. Reitman S. and Frankel, S (1957):**
Colorimetric determination of serum activity of GOT and GPT enzymes.
Am. J. Clin. Path.; 28:56.
- 295. Perfetto, F., Tarquini, R., De-Leonardis, V., Piluso, A., Becucci, A., Anselmi, B., Curradi, C., Tapparini, L. and Tarquini, B. (1998):**
Vascular damage and not hypertension per se influences endothelin-1 plasma levels in patients with non-insulin diabetes mellitus.
Recenti. Prog. Med.; 88(7-8): 317-20.
- 296. Perico, N., Cornego, R. and Benigini, A. (1991):**
Endothelin induce diuresis and natriuresis in the rat by acting on proximal convulated tubular cell through a mechanism mediated by lipooxygenase products.
J. Am. Soc. Nephrol.; 2: 57.
- 297. Pernow, J., Hensen, A. and Lundberg, J.M. (1989):**
Tissue specific distribution, clearance and vascular effect of endothelin in pigs.
Biochem. Biophys. Res. Commun.; 161: 647.
- 298. Peterson, H.R., Rothschild, M., Weinberg, C.R., Fell, R.D., Mcleish, K.R. and Pfeifer, M.A. (1988):**
Body fat and the activity of the autonomic nervous system.
N. Eng. J. Med.; 318: 1077-83.
- 299. Pfeifer, M.A., Cook, D., Brodsky, J., Tice, D., Reenan, A., Swedine S., Halter, J.B. and Porte, D. (1982):**
Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic men.
Diabetes; 31: 33-45.

- 300. Pirat, J. (1965):**
Diabetic nephropathy.
Diabetes; 14: 1-9.
- 301. Pittile, R.M., Clarke, J.M, and Harris, D. (1984):**
Cigarette smoking and platelet adhesion.
Br. J. Haematol.; 58: 627-32.
- 302. Pooling Project Research Group (1993):**
Relationship of blood pressure and ECG abnormalities to incidence of H.I.
Arch. Int. Med.; 153: 596
- 303. Porstmann, T. and Kiessig, S.T. (1992):**
Enzyme immunoassay techniques: An overview.
J. Immunological Methods; 150: 5-21.
- 304. Powers, P.S. (1980):**
Obesity: the regulation of weight, 2nd ed.; Williams and Wilkins Co.,
Baltimore; Pp: 105.
- 305. Prasad, K., Lee, P. and Kalra, J. (1991):**
Influence of insulin on cardiovascular function, oxygen free radicals and
blood chemistry.
Am. Heart J.; 121(91): 178.
- 306. Raine, A.E.G. (1994):**
Hypertension and the kidney.
Br. Med. Bull.; 50: 322-41.
- 307. Ravussin, E., Burnard, B., Schutz, Y. and Jequier, E. (1982):**
Twenty-four hours energy expenditure and resting metabolic rate in obese,
moderately obese, and control subjects.
Am. J. Clinic. Nutr.; 35: 566-73.
- 308. Ren-Ming, H., Levin, E., Pedram, A. and Frank, H. (1993):**
Insulin stimulates production and secretion of endothelin from bovine
endothelial cells.
Diabetes; 42: 351-8
- 309. Resnick, L.M. (1991):**
Calcium metabolism in hypertension and allied metabolic disorders.
Diabetes Care; 14: 505-20.
- 310. Robert, P., Gillard, V., Plas, P., Chubrier, P. and Guillon, J. (1989):**
Angiotensin II and phosphodiastase potentially down-regulate endothelin-1
binding sites in vascular smooth muscle cells.
Biochem. Biophys. Res. Commun.; 164: 809.

311. Robertson, R., Susawa, T., Sugiura, M., Haile, V. and Inagam, T. (1990):
Circulating endothelin levels: Modulation by heart failure in man
Clin. Res.; 38(2): 414.
312. Roccatello, D., Mosso, R. and Ferro, M. (1994):
Urinary endothelin in glomerulonephritis patients with abnormal renal function.
Clin. Nephrol.; 41(6): 323.
313. Rocchini, A.P., Moorehead, C., London, M. and Antishin, K. (1990):
Salt sensitivity and insulin resistance.
Circulation; 82: 111-87.
314. Roche, A.F., Siervogen, R.M. and Chumlea W.C. (1981):
Grading of body fatness from anthropometric data.
Am. J. Clinic. Nutr.; 43: 2831-8.
315. Rockey, D.C. (1995):
Characterization of endothelin receptors mediating rat hepatic stellate cell contraction.
Biochem. Biophys. Res. Commun.; 168: 537.
316. Romero, J.C., Levin, E.R. and Knox, F.G. (1988):
Mechanisms underlying pressure related natiuresis: The role of rennin angiotensin and prostaglandin systems.
Hypertension; 11: 724-38.
317. Rossi, M., Marti, G., Ricordi, L., Fornasari, G., Finardi, G., Frantino, P. and Bernardi, L. (1988):
Clinical Science; 76: 567-72.
318. Rosskopf, D., Dusing, K. and Siffert, W. (1993):
Membrane sodium-proton exchange and primary hypertension.
Hypertension; 21: 607-17.
319. Rowe, J.W., Young, J.B. and Minaker, K.L. (1981):
Effect of insulin and glucose infusion on sympathetic nervous system activity in normal man.
Diabetes; 30: 219-25.
320. Rubert, W., McMurray, J.R. and David, V. (1989):
Weight reduction decreases atrial natiuretic factor and blood pressure in obese patients.
Metabolism; 38: 1231-71.

- 321. Ruilope, L.M. (1993):**
Kidney and etiology, pathology and management of essential hypertension.
J. Hum. Hypertens.; 7(Suppl. 1): 37-41.
- 322. Ruilope, L.M., Lahera, V., Rodicio, J.L. and Romero, J. (1994):**
Is renal hemodynamics a key factor in the development and maintenance
of arterial hypertension in humans?
Hypertension; 23: 3-9.
- 323. Russel, M.R. (1992):**
Nutrient assessment. In: Wyngaarden, J.B., Smith, L.H. and Bennett, J.C.
(ed.): Cecil Textbook of Medicine, 19th ed., W.B. Saunders Co.,
Philadelphia; Pp: 1151-4.
- 324. Safar, M.J. (1988):**
Therapeutic trials in hypertension.
Am. H. J.; 115-702.
- 325. Saito, T., Nakoa, K., Mukoyama, M. and Imura, H. (1990):**
Increased plasma level in patients with essential hypertension.
N. Eng. J. Med.; 322(3): 205.
- 326. Sakamoto, H., Sasaki, S., Hirata, Y., Imai, T., Ando, K. and Ida, T. (1990):**
Production of endothelin-1 by rat cultured mesangial cells.
Biochem. Biophys. Res. Commun.; 169: 462-70.
- 327. Salvetti, A., Brogi, G., Dilegge, V. and Bernini, G.P. (1993):**
The inter-relationship between insulin resistance and hypertension.
Drugs; 46(Suppl. 2): 149-59.
- 328. Samani, N.J. (1994):**
Molecular genetics of susceptibility to the development of hypertension.
Br. Med. Bull.; 50: 260-7.
- 329. Samson, W.K., Skalak, A. and Haung, F. (1990):**
Pituitary site of action of endothelin: Selective inhibition of prolactin release
in vitro.
Biochem. Biophys. Res. Commun.; 169: 737.
- 330. Sandok, E., Lerman, A. and Stingo, A. (1992):**
Endothelin in a model of acute renal dysfunction: Modulating action of atrial
natriuretic factor.
J. Am. Soc. Nephrol.; 3: 196.

- 331. Santuscci, A., Ferri, C., Cammarella, I., Valentino, S., Bellini, C., Tani, S., Musca, A. and Balsano, F. (1990):**
Plasma atrial natruretic peptide in young normotensive subjects with a family history of hypertension and in young normotensive patients.
Am. J. Hypertens.; 3: 782-5.
- 332. Sawamura, T., Kimura, S. and Shinmi, O. (1990):**
Characterization of endothelin converting enzyme activities in soluble fraction of bovine cultured endothelial cells.
Biochem. Biophys. Res. Commun.; 169: 1138.
- 333. Schall, J.M., Benacerraf, A. and Ducimetiere, P. (1985):**
Comparison of risk factors in vasospastic angina without significant fixed coronary narrowing to significant fixed coronary narrowing and no vasospastic angina.
Am. J. Cardiol.; 57: 199-202
- 334. Scheletter, G. and Nussel, E. (1975):**
In methods of enzymatic analysis, Vol. 5, Bergmeyer, H.U., ed. Academic Press, New York, Pp: 1831-5.
- 335. Schiffrin, E.L., Intengan, H.D., Thibault, G. and Touyz, R.M. (1997):**
Clinical significance of endothelin in cardiovascular disease
Curr. Opin. Cardiol.; 12 (4): 354-7.
- 336. Schini, V., Junguero, D., Scott-Burden, T. and Vanhoutte, P. (1991):**
Interleukin-1 beta induces the production of an L-arginine derived relaxing factor from cultured smooth muscle cells from rat aorta.
Biochem. Biophys. Res. Commun.; 168: 537.
- 337. Schleiffer, R., Galluser, M. and Kachethoffer, J., Raud, F. (1994):**
Diatery calcium supplementation, blood pressure and intestinal Ca^{42} absorption.
Am. J. Med. Sci.; 307 (Suppl. 1): S116-9: 823-8.
- 338. Schmit, E.R. (1964):**
Colorimetric determination of total lipids.
Exp. Med.; 137: 545.
- 339. Sealy, J.E., Blumenfeld, J.D., Bell, G.M., Pecker, M.S., Sommers, S.C. and Laragh J.H. (1988):**
On the renal basis of essential hypertension: Nephron causing a hypertensive vasoconstriction-volume relationship.
J. Hypertens.; 6: 863-77.

- 340. Sevensen, P.A., Christiansen, J.S., Soegard, U., Welinder, B.S. and Nerup, J. (1980):**
Rapid changes in chromatographically determined hemoglobin A₁ induced by short-term changes in glucose concentration.
Diabetologia; 19: 130-6.
- 341. Shami, S.K. and Chittenden, S.J. (1991):**
Microangiopathy in diabetes mellitus: Features, Complications and Investigations
Diabetes Res.; 1794): 157-68.
- 342. Shibouta, Y., Suzuki, N. and Shino, A. (1990):**
Pathophysiological role of endothelin in acute renal failure
Life Sci.; 46: 4611.
- 343. Shichiri, M., Hirata, Y. and Nakajima, T. (1991):**
Endothelin-1: An autocrine/paracrine growth factor for human cancer cell lines.
J. Clin. Invest.; 87: 1867.
- 344. Shimada, K., Matsushita, Y. and Wakabayashi, K. (1995):**
Cloning and functional expression of human endothelin converting enzyme.
Biochem. Biophys. Res. Commun.; 168: 537.
- 345. Shoback, D.M., Williams, G.H., Moore, T.J., Dluhy, R.G., Podolsky, S. and Hollenberg N.K. (1983):**
Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.
J. Clin. Invest.; 72: 2115-24.
- 346. Shymala, V., Moulthrop, T.H, Stratton, J. and Tekamp, P. (1994):**
Two endothelin b receptors generated by alternative splicing from single gene.
Cell Met. Biol. Res.; 40(4): 285.
- 347. Siegler, R., Edwin, S., Christfferson, R. and Mitchell, M. (1991):**
Endothelin in the urine of children with hemolytic uremic syndrome.
Ped.; 88: 1063-8.
- 348. Simons, L.A. (1986):**
Blood pressure and risk of fatal coronary heart disease.
Hypertension; 13(Suppl. 1): 1-12.

- 349. Simonson, M.S., Jones, J.M. and Dunn, M. (1992):**
Different regulation of FOS and JUN gene expression and AP01 CIS element activity by endothelin peptides: Possible implication for mitogenic signaling by endothelin.
J. Biol. Chem.; 267: 8649.
Hypertension; 5(2): 5
- 350. Sloand, J.A., Hooper, M. and Izzo, J.L. (1989):**
Effects of circulating norepinephrine on platelets, leucocytes and RBCs count by alpha-1-adrenergic stimulation
Am. J. Cardiol.; 63: 140-2.
- 351. Solberg, L.A. and Strong, J.P. (1983):**
Risk factors and atherosclerotic lesions: A review of autopsy studies.
Atherosclerosis; 3: 187-98.
- 352. Solt, V., Brown, M., Kennedy, B., Kolterman, O. and Ziegler, M. (1990):**
Elevated insulin, norepinephrin and neuropeptide Y in hypertension.
Am. J. Hypertens.; 3: 823-8.
- 353. Sowers J.R., Standley, P.R., Ram, J., Jacober, S., Simpson, L. and Rose, K. (1993):**
Hyperinsulinemia, insulin resistance and hypertension: Contributing factors in the pathogenesis of hypertension and atherosclerosis
Am. J. Hypertens.; 6 (Suppl. 1): S260-70.
- 354. Stamler, J. (1993):**
Isolated systolic hypertension.
Arch. Internal Medicine; 154: 2128-35.
- 355. Standley, P.R., Bakir, M.H. and Sower, J.R. (1993):**
Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis.
Am. J. Kidney Dis; 21(6 suppl. 3): 39-46.
- 356. Standen, N.B., Quayle, J.M. and Davies, N.W. (1989):**
Hyperpolarizing vasodilators activate ATP sensitive K⁺ channels in arterial smooth muscles.
Science; 245: 177-80
- 357. Stanimirovic, D., McCarron, R. and Spatz, M. (1994):**
Dexamethasone down regulates endothelin receptors in human cerebrovascular endothelial cells.
Neuropeptides; 26(3): 145.

- 358. Stasch, P. and Kazda, S. (1989):**
Endothelin-1 induced vascular contractions: Interactions with drugs affecting the calcium channel.
J. Cardiovasc. Pharmacol.; 13 (Suppl. 5): 563-9.
- 359. Stein, N. (1986):**
Analysis of total cholesterol: A colorimetric method.
Clin. Chem. Acta; 26: 763.
- 360. Stehower, C.D. (1993):**
Clinical usefulness of measurement of urinary albumin excretion in diabetes mellitus.
Neth. J. Med.; 42(5-6): 175-86
- 361. Stingo, A., Clavell, A., Aarthus, L. and Burnett, J. (1993):**
Biological role of endothelin-1 receptor in aortic cross clamping.
Hypertension, 22(1): 62.
- 362. Sugiura, M., Inagami, T. and Kon, V. (1989):**
Endotoxin stimulates endothelin release in vivo and in vitro as determined by radioimmunoassay.
Biochem. Biophys. Res. Commun.; 161: 1220.
- 363. Swedberg, K.B. (1998):**
Impact of neuroendocrine activation on coronary artery disease
Am. J. Cardiol.; 82(3A): 8H-14H.
- 364. Tabouchi, Y., Nakamura, M., Rakugi, H. and Ogihara, T. (1989):**
Endothelin inhibits presynaptic adrenergic neurotransmission in rat mesenteric artery
Biochem. Biophys. Res. Commun.; 161: 803.
- 365. Takagi, Y., Fukase, M and Takata, S. (1990):**
Autocrine effect of endothelin on DNA synthesis in human vascular endothelial cells.
Biochem. Biophys. Res. Commun.; 168: 537.
- 366. Takabatake, T., Ise, T., Ahta, K. and Kobayashi, K. (1991):**
Effect of endothelin on hemodynamics and tubuloglomerular feedback.
Am. J. Physiol.; 263: F108.
- 367. Takahashi, Y., Jones, P. and Kanse, M. (1990):**
Endothelin in the gastrointestinal tract: Presence of endothelin-like immunoreactivity, endothelin-1 messenger RNA, endothelin receptors and pharmacological effect.
Gastroenterology; 99: 1660.

- 368. Takeda, Y., Miyamori, I., Yoneda, T. and Takeda, R. (1991):**
Production of endothelin-1 from the mesenteric arteries of streptozocin-induced diabetic rats.
Life Sci.; 48: 2253-6.
- 369. Takuwa, Y., Kasuya, Y. and Takuwa, N. (1990):**
Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells.
J. Clin. Invest.; 5: 653-61.
- 370. Tanaka, A., Tagagiri, K. and Hoshino, M. (1995):**
Endothelin-1 stimulates bile acid secretion and vesicular transport in the isolated perfused rat liver.
Am. J. Physiol. Gastrointest. Liver Physiol.; 266(2): 29.
- 371. Tegos, R. and Beutler, E. (1980):**
Glycosylated hemoglobin A₂ components.
Blood; 56: 571.
- 372. Teuscher, A.U., Lerch, M., Shaw, S., Pacini, G., Ferrari, P. and Weidmann, P. (1998):**
Endothelin-1 infusion inhibits plasma insulin responsiveness in normal men.
J. Hypertens.; 16 (9): 1279-84.
- 373. Tomita, K., Ujiie, K. and Nakanishi, T. (1990):**
Plasma endothelin level in acute renal failure.
N. Eng. J. Med.; 321: 1127.
- 374. Tooke, J. E. (1989):**
Microcirculation and diabetes.
Br. Med. Bull.; 45(1): 206.
- 375. Toyoshima, H., Park, Y.G. and Ishikawa, Y. (1982):**
Effects of ventricular hypertrophy on conduction velocity of activation front in the ventricular myocardium.
Am. J. Cardiol.; 49: 1938-45
- 376. Trinder P, (1969):**
Enzymatic determination of glucose
Ann. Clin. Biochem.; 6:24.
- 377. Trippler, B., Herbst, C. and Simmet, T. (1994):**
Endothelin influences pH of plasma platelet through protein kinase C mediated pathways.

- Thromb. Res.; 78(1): 55.
- 378. Turner, J., McNichol, M. and Sillett, R. (1986):**
Distribution of carboxyhemoglobin concentration in smokers and non-smokers.
Thorax, 41: 25-7.
- 379. Uchida, K., Terada, Y. and Nonoguchi, H. (1992):**
Messenger RNA expression and synthesis of endothelin-1 along renal nephron segments.
J. Clin. Invest.; 90: 1043.
- 380. Uchihara, M., Izumi, N., Sato, C. and Marumo, F. (1992):**
Clinical significance of elevated plasma endothelin-1 in patients with liver cirrhosis
Hepatology; 61(1): 95.
- 381. Ujiie, K., Terada, Y. and Nonoguchi, H. (1992):**
Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments.
J. Clin. Invest., 90: 1043.
- 382. Vague, P., Juhan-Vague, I., Ailhaud, M., Badier, C., Viard, R., Alessi, M. and Collen, D. (1986):**
Correlation between blood fibrinolytic activity, plasminogen activator-inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.
Metabolism; 35: 250-263.
- 383. Veglio, F., Bertello, P., Pinna, G., Mulatero, P., Rossi, A., Gurioli, I., Panarelli, M. and Chlandussi, L. (1993):**
Plasma endothelin in essential hypertension and diabetes.
J. Hum. Hypertens.; 7: 321-5.
- 384. Vermes, I., Beishuzein, A. and Haanen C. (1995):**
Dissociation of plasma adrenocorticotropin and cortisol level in critically ill patients: Possible role of endothelin and atrial natriuretic hormone.
J. Clin. Endocrinol. Metab.; 80(4): 1238.
- 385. Viberti, G. (1993):**
Pathophysiology of renal and vascular disorders in insulin-dependent diabetes.
Am. J. Hypertens.; 1355-95.

- 396. Widness, J., Rogler, B. and McCormik, K.L. (1980):**
Rapid fluctuation in glycohemoglobin (A_{1c}) related to acute changes in glucose.
J. Lab. Clin. Med.; 95: 386-94.
- 397. Wilhelmsen, L., Svardsudd, K., Korsan-Bengsten, K., Larsson, B., Welin, L. and Tibblin, G. (1984):**
Fibrinogen as a risk factor for stroke and myocardial infarction.
N. Eng. Med. J.; 311: 501-5.
- 398. Wilkes, B., Mento, P., Hollander, A., Maita, M., Sung, S. and Girardi, E. (1990):**
Endothelin receptors in human placenta relationship to vascular resistance and thromboxane release.
Am. J. Physiol.; 258: 864-70.
- 399. Williams, G.H. (1994):**
Essential hypertension as an endocrine disease.
Endocrinol. Metab. Clin. North Am.; 23(2): 429-43.
- 400. Williams, G., Haynes, H. and David, J. (1993):**
The endothelin family of peptides: Local hormones with diverse roles in health and disease.
Clinical Science; 84: 485-500.
- 401. Winkler, G., Lakatos, P., Nagy, Z., Speer, G., Salamon, F., Szekers, O., Kovacs, M. and Cseh, K. (1998):**
Elevated serum tumor necrosis factor- α and endothelin-1 levels correlate with increased C-peptide concentration in android type obesity.
Diabetes Care; 21 (10): 1778-9.
- 402. Wintrobe, M., Lee, C., Roggs, D., Bithell, T., Athens, J. and Lukens, J. (1981):**
Clinical hematology, 8th ed.; Pp:90-6.
- 403. Wiseman, M., Viberti, G., Mackintosh, D., Jarrett, R.J. and Keen, H. (1984):**
Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus.
Diabetologia; 26: 401-5.
- 404. WHO Expert Committee: Second report on diabetes mellitus (1980):**
WHO technical report series No. 26.
Geneva; WHO.

405. Wright, J.W. and Harding, J.W. (1992):

Regulatory role of brain angiotensins in the control of physiological and behavioral responses.

Brain Res.; 17: 227-62.

406. Xavier, F. (1992):

Obesity. In: Wyngaarden, J.B., Smith, L.H. and Bennett, J.C. (ed.): Cecil Textbook of medicine, 19th ed., W.B. Saunders Co., Philadelphia, Rp: 1162-9

407. Yachnaiga, M., Chijiwa, Y. and Misawa, T. (1992):

Endothelin B receptor on gunia pig small intestine smooth muscle cells.

Am. J. Physiol. Gastroints.; 262 (2): 225.

408. Yanagisawa, M., Kurihara, H. and Kimura, S. (1988):

A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Nature; 332: 411-26.

409. Yanagisawa, M., Kurihara, H. and Kimura, S. (1989):

The human preproendothelin-1 gene: Possible regulation by endothelial phosphoinositide turn over signaling.

J. Cardiovasculasc. Pharmacol.; 13: S13.

410. Yang, X.Y., Fekete, Z., Gardner, J., Beneventia, J. and Aviv, A. (1994):

Endothelin mobilizes and enhances glucose uptake in cultured human skeletal muscle myoblasts and L6 myotubules.

Hypertension; 23(6 part 2): 1075-81.

411. Yamasaki, H., Niwa, M., and Yamashita, K. (1989):

Specific endothelin-1 binding sites in the arterioentricular node of the procine heart.

Eur. J. Pharmacol. ; 168: 247.

412. Yip, J., Mattock, M.B., Morocatti, A., Sethi, M., Trevisan, R. and Viberti, G. (1993):

Insulin resistance in insulin dependent diabetic patients with microalbuminuria.

Lancet; 342 (8876): 883-7.

413. Ylikorkala, O., Cacciatore, B., Paakkari, I., Tikkanen, M.J., Viinikka, L. and Toivonen, J. (1998):

The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane.